Biocon Biologics secures 3-year contract from Ministry of Health Malaysia

29 Apr 2022 , 01:33 AM

Biocon Biologics a subsidiary of Biocon announced that its subsidiary Biocon Sdn Bhd in Malaysia has been awarded a three-year contract valued at USD 90 million for its recombinant human insulin brand Insugen by the Ministry of Health Malaysia Biocon Sdn Bhd will manufacture and supply its range of insulins to its partners Duopharma Marketing Sdn Bhd a subsidiary of Duopharma Biotech a leading pharmaceutical and biotech company in Malaysia Biocon Biologics Insugen formulations will be available to patients at all Ministry of Health hospitals district health offices and health clinics